839
TRENDS IN NEOADJUVANT CHEMOTHERAPY UTILIZATION AND TREATMENT SEQUENCING FOR GASTRIC CANCER: ARE WE MAKING PROGRESS?
Date
May 20, 2024
Background
Over the past two decades, guidelines for gastric cancer (GC) have shifted. NCCN guidelines recommend chemotherapy for patients with stage IB and beyond. While surgery is an essential part of treatment, perioperative chemotherapy (PCT) and neoadjuvant chemotherapy (NCT) have proven to be superior to surgery with or without adjuvant chemotherapy (ACT). However, NCT is not universally practiced, and the reasons are ill-defined. This study investigates national rates, trends, and factors affecting NCT utilization.
Patients and Methods
Using the National Cancer Database, patients diagnosed with stage 1B-3 gastric cancer from 2010-2020 were identified. Changes in chemotherapy sequence over time were identified. We performed multivariable regression models to assess factors affecting the receipt of each type of treatment (NCT, PCT, ACT, or none). Factors included age, sex, race, ethnicity, insurance, the Charleson Comorbidity Index, clinical stage, facility type, distance to facility (miles), and case volume.
Results
A total of 10,808 patients met criteria, and 73.9% were female. Mean age of the cohort was 63 (12) years. The majority of the cohort 57.0% (n=6,164) had NCT and NCT utilization increased incrementally over the study period with 68.9% of patients receiving NCT. Factors affecting utilization of NCT were age [OR 0.90 (0.89, 0.91], female sex [OR 0.54 (0.46,0.63)], race [Black OR 0.44 (0.35,0.55); AAPI OR 0.47 (0.36,0.62)], Hispanic ethnicity [OR 0.46 (0.36,0.59)], CCI [1 OR 0.74 (0.63,0.88); 2 0.59 (0.45,0.77)], institutional case volume [OR 1.01 (1.01, 1.01)], stage [II OR 2.87 (1.94,4.23); III OR 4.47 (3.05,6.57)], and insurance status [private OR 2.94 (1.96,4.43); Medicare OR 3.59 (2.37,5.42), other government OR 3.15 (1.45, 6.83)].
Conclusion
This study is the first to define national trends in chemotherapy sequencing in GC in a national cohort. Moreover, our findings highlight the multifaceted determinants of NCT use in GC management, underscoring the need for tailored strategies to optimize access and adherence to evidence-based treatment protocols across diverse patient populations.
Over the past two decades, guidelines for gastric cancer (GC) have shifted. NCCN guidelines recommend chemotherapy for patients with stage IB and beyond. While surgery is an essential part of treatment, perioperative chemotherapy (PCT) and neoadjuvant chemotherapy (NCT) have proven to be superior to surgery with or without adjuvant chemotherapy (ACT). However, NCT is not universally practiced, and the reasons are ill-defined. This study investigates national rates, trends, and factors affecting NCT utilization.
Patients and Methods
Using the National Cancer Database, patients diagnosed with stage 1B-3 gastric cancer from 2010-2020 were identified. Changes in chemotherapy sequence over time were identified. We performed multivariable regression models to assess factors affecting the receipt of each type of treatment (NCT, PCT, ACT, or none). Factors included age, sex, race, ethnicity, insurance, the Charleson Comorbidity Index, clinical stage, facility type, distance to facility (miles), and case volume.
Results
A total of 10,808 patients met criteria, and 73.9% were female. Mean age of the cohort was 63 (12) years. The majority of the cohort 57.0% (n=6,164) had NCT and NCT utilization increased incrementally over the study period with 68.9% of patients receiving NCT. Factors affecting utilization of NCT were age [OR 0.90 (0.89, 0.91], female sex [OR 0.54 (0.46,0.63)], race [Black OR 0.44 (0.35,0.55); AAPI OR 0.47 (0.36,0.62)], Hispanic ethnicity [OR 0.46 (0.36,0.59)], CCI [1 OR 0.74 (0.63,0.88); 2 0.59 (0.45,0.77)], institutional case volume [OR 1.01 (1.01, 1.01)], stage [II OR 2.87 (1.94,4.23); III OR 4.47 (3.05,6.57)], and insurance status [private OR 2.94 (1.96,4.43); Medicare OR 3.59 (2.37,5.42), other government OR 3.15 (1.45, 6.83)].
Conclusion
This study is the first to define national trends in chemotherapy sequencing in GC in a national cohort. Moreover, our findings highlight the multifaceted determinants of NCT use in GC management, underscoring the need for tailored strategies to optimize access and adherence to evidence-based treatment protocols across diverse patient populations.
Tracks
Related Products
RIGHT POSTERIOR BILE DUCT INJURY RECONSTRUCTION WITH ROBOTIC RY HEPATICOJEJUNOSTOMY
Right posterior bile duct injury with disconnected duct syndrome creates diagnostic challenges for many endoscopists and radiologists. The diagnosis and treatment are often delayed…
LAPAROSCOPIC ESOPHAGOGASTROSTOMY AS A SALVAGE OPERATION AFTER FAILED MYOTOMY IN END-STAGE ACHALASIA
End-stage achalasia is characterized by massive and tortuous esophagus with malnutrition, progressive dysphagia, and vomiting. Esophagectomy is indicated in those with a tortuous esophagus with axis deviation, failed myotomy, and deteriorating quality of life…
ROBOTIC ANATOMICAL RIGHT HEPATECTOMY FOR NECROTIC CHOLANGIOCARCINOMA
TECHNIQUE OF INFLOW CONTROL IN NAKAMURA TYPE B PORTAL VEIN ANATOMY
Anatomical variations in the inflow vasculatures must be anticipated in any anatomical hepatectomy to avoid complications. Nakamura Type B portal vein (PV) anatomy requires individual isolation of right anterior and posterior PV to avoid narrowing of the left PV…
THE PERFECT STORM: LAPAROSCOPIC TRANSCHOLEDOCHAL BILE DUCT EXPLORATION FOR BILE DUCT BEZOAR IN ADVANCED CIRRHOSIS WITH PORTAL HYPERTENSION
Transcholedochal laparoscopic bile duct exploration is a challenging procedure. Advanced cirrhosis with portal hypertension is associated with unique set of challenges not limited to increased risk of bleeding and fragile liver…
